Form 4: Sotera Health CEO Michael Petras Jr. Reports Stock Transactions
SEC Form 4
Sotera Health's CEO, Michael B. Petras Jr., reports the acquisition and disposal of company stock, including transactions related to vesting of restricted stock units (RSUs) and an underwritten public secondary offering.
Summary
- Michael B. Petras Jr., CEO of Sotera Health, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On March 2, 2024, shares were withheld to cover tax obligations upon the vesting of 62,406 RSUs at a price of $14.56.
- An additional withholding occurred on March 2, 2024, for tax obligations related to the vesting of 71,063 RSUs, also at $14.56.
- On March 4, 2024, Petras was granted 274,160 RSUs.
- Also on March 4, 2024, Petras sold 1,003,870 shares of common stock at $14.3075 per share in an underwritten public secondary offering.
- Following these transactions, Petras directly owns 699,749 shares and indirectly owns 5,453,580 shares through a grantor trust.
- Additionally, Petras was granted 544,509 stock options on March 4, 2024, exercisable at $14.59, vesting in three equal annual installments starting March 2, 2025.
- The filing also references previously reported stock options granted in 2020, 2022 and 2023 with various vesting schedules and exercise prices.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the CEO's stock ownership.
Future Outlook
The RSUs granted on March 4, 2024, vest annually in three equal installments commencing March 2, 2025.
Industry Context
Executive stock transactions are routinely monitored by investors as they can provide insights into management's confidence in the company's future prospects. Sales of large blocks of stock, such as the one reported here, are often scrutinized for their potential impact on the stock price.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are common in publicly traded companies like Sotera Health to align management's interests with those of shareholders.
- The vesting schedules and exercise prices of the stock options appear to be within typical ranges for similar companies.
- The sale of shares in a secondary offering is a standard practice for executives to diversify their holdings.
Stakeholder Impact
- Shareholders may be interested in the CEO's stock transactions as an indicator of management's view of the company's value.
- The sale of a significant number of shares in a secondary offering could potentially impact the stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 2020-11-20 | Stock options granted under the 2020 Incentive Plan. |
| 2022-03-02 | Stock options granted under the 2020 Incentive Plan. |
| 2022-11-07 | Stock options granted under the 2020 Incentive Plan. |
| 2023-03-06 | Stock options granted under the 2020 Incentive Plan. |
| 2024-02-29 | Filing of Prospectus 424(b)(7) with the SEC. |
| 2024-03-02 | Shares withheld for tax obligations on vesting RSUs. |
| 2024-03-04 | Grant of RSUs and sale of shares in a public offering. |
| 2024-03-05 | Date of the filing. |
| 2024-03-04 | Grant of stock options. |
| 2030-11-20 | Expiration date of stock options granted on November 20, 2020. |
| 2032-03-02 | Expiration date of stock options granted on March 2, 2022. |
| 2032-11-07 | Expiration date of stock options granted on November 7, 2022. |
| 2033-03-06 | Expiration date of stock options granted on March 6, 2023. |
| 2034-03-04 | Expiration date of stock options granted on March 4, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.